Last reviewed · How we verify

low dose combination of MMF and Tac

Tuen Mun Hospital · FDA-approved active Small molecule Quality 0/100

low dose combination of MMF and Tac is a Small molecule drug developed by Tuen Mun Hospital. It is currently FDA-approved. Also known as: Cellcept and Prograf.

At a glance

Generic namelow dose combination of MMF and Tac
Also known asCellcept and Prograf
SponsorTuen Mun Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about low dose combination of MMF and Tac

What is low dose combination of MMF and Tac?

low dose combination of MMF and Tac is a Small molecule drug developed by Tuen Mun Hospital.

Who makes low dose combination of MMF and Tac?

low dose combination of MMF and Tac is developed and marketed by Tuen Mun Hospital (see full Tuen Mun Hospital pipeline at /company/tuen-mun-hospital).

Is low dose combination of MMF and Tac also known as anything else?

low dose combination of MMF and Tac is also known as Cellcept and Prograf.

What development phase is low dose combination of MMF and Tac in?

low dose combination of MMF and Tac is FDA-approved (marketed).

Related